Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Abstract Background Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long ter...

Full description

Bibliographic Details
Published in:	Respiratory Research
Main Authors:	Alberto M. Marra, Michael Halank, Nicola Benjamin, Eduardo Bossone, Antonio Cittadini, Christina A. Eichstaedt, Benjamin Egenlauf, Satenik Harutyunova, Christine Fischer, Henning Gall, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Tobias J. Lange, Karen M. Olsson, Hans Klose, Ekkehard Grünig
Format:	Article
Language:	English
Published:	BMC 2018-12-01
Subjects:	Pulmonary hypertension Pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension Riociguat Soluble guanylate cyclase stimulator Right atrial area
Online Access:	http://link.springer.com/article/10.1186/s12931-018-0957-y

Similar Items

Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
by: N. H. Kim
Published: (2010-03-01)

Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective
by: Mihalek AD, et al.
Published: (2022-10-01)

The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
by: S. E. Gratsianskaya, et al.
Published: (2020-10-01)

Modern view on the place of riociguat in the treatment of pulmonary hypertension
by: Z S Valieva, et al.
Published: (2018-04-01)

CLINICAL CASE OF REPLACEMENT OF ENDOTHELIN RECEPTOR ANTAGONIST (BOSENTAN) BY SOLUBLE GUANYLATE CYCLASE STIMULATOR (RIOCIGUAT) IN THE PATIENT WITH PULMONARY ARTERIAL HYPERTENSION
by: E. A. Devetyarova, et al.
Published: (2018-06-01)

Pharmacological effects of a new soluble guanylate cyclase stimulator in experimental pulmonary arterial hypertension
by: V. V. Bykov, et al.
Published: (2023-04-01)

Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy
by: H. A. Ghofrani, et al.
Published: (2009-03-01)

Better efficacy of sequential combination with balloon pulmonary angioplasty after long‐term riociguat for patients with inoperable chronic thromboembolic pulmonary hypertension
by: Wei Wang, et al.
Published: (2024-07-01)

Soluble Guanylyl Cyclase Activators—Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension
by: Grzegorz Grześk, et al.
Published: (2023-01-01)

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
by: Humberto García Aguilar, et al.
Published: (2022-07-01)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
by: Lian TY, et al.
Published: (2017-04-01)

Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results
by: E. V. Filippov
Published: (2020-12-01)

Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: N. A. Tsareva, et al.
Published: (2016-12-01)

Results of long-term riociguat therapy, including a switching strategy from sildenafil, in patients with pulmonary hypertension of various genesis
by: S. A. Musashaykhova, et al.
Published: (2023-11-01)

THE ROLE OF RIOCIGUAT IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE
by: O. Ya. Vasiltseva, et al.
Published: (2019-12-01)

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study
by: Julia Degering, et al.
Published: (2023-01-01)

Long-term oxygen therapy in precapillary pulmonary hypertension – SOPHA study
by: Nicola Benjamin, et al.
Published: (2024-09-01)

Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data
by: M. A. Simakova, et al.
Published: (2020-05-01)

Meta‐Analysis of Real‐World Clinical Practice to Assess the Effectiveness of Riociguat in Treating Chronic Thromboembolic Pulmonary Hypertension
by: Esra Pamukçu, et al.
Published: (2025-02-01)

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide
by: L. T. Domingo, et al.
Published: (2022-12-01)

Advances in Balloon Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
by: GAO Luyang, et al.
Published: (2023-09-01)

Nitric oxide activates AMPK by modulating PDE3A in human pulmonary artery smooth muscle cells
by: Julie Dillard, et al.
Published: (2020-09-01)

Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways
by: Katharina Nubbemeyer, et al.
Published: (2025-04-01)

Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty – A randomized controlled study
by: Tatsuo Aoki, et al.
Published: (2020-08-01)

Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
by: Yi Tong, et al.
Published: (2018-09-01)

Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients
by: N. V. Marukyan, et al.
Published: (2021-05-01)

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
by: Yu-Yang Liu, et al.
Published: (2023-01-01)

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
by: Yu-Yang Liu, et al.
Published: (2023-02-01)

Rehabilitation in patients with pulmonary arterial hypertension
by: Stephan Keusch, et al.
Published: (2017-07-01)

Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension
by: Erin M. Schikowski, et al.
Published: (2022-11-01)

Modern possibilities of echocardiographic diagnosis in pulmonary arterial hypertension
by: A. A. Klimenko, et al.
Published: (2025-01-01)

EFFICACY OF MULTIDISCIPLINARY MANAGEMENT OF PULMONARY HYPERTENSION
by: I. R. Gaisin, et al.
Published: (2017-02-01)

The impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension - results of a retrospective clinical registry
by: Pavel Jansa, et al.
Published: (2021-06-01)

Possibilities of long-term effective treatment of idiopathic pulmonary arterial hypertension by replacing sildenafil with riociguat and using sequential combination therapy: case report
by: S. A. Musashaykhova, et al.
Published: (2022-12-01)

Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
by: Bajwa EK, et al.
Published: (2024-05-01)

Predicting Response to Switching From Phosphodiesterase Type 5 Inhibitor to Riociguat in Patients With Pulmonary Arterial Hypertension: Biomarker and Responder Analysis of the RESPITE and REPLACE Studies
by: James R. Klinger, et al.
Published: (2025-07-01)

Recent trends in pulmonary arterial hypertension
by: Rajagopalan Natarajan
Published: (2011-01-01)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
by: Max Wissmüller, et al.
Published: (2022-10-01)

A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?
by: N A Tsareva, et al.
Published: (2017-09-01)

Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
by: Munish Sharma, et al.
Published: (2021-04-01)